Equities

Mabwell Shanghai Bioscience Co Ltd

688062:SHH

Mabwell Shanghai Bioscience Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)24.65
  • Today's Change0.68 / 2.84%
  • Shares traded7.67m
  • 1 Year change-7.02%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,6952,55194
Total Receivables, Net16110769
Total Inventory1597940
Prepaid expenses274128
Other current assets, total6.220.0215
Total current assets2,0482,778245
Property, plant & equipment, net2,0021,479908
Goodwill, net119119119
Intangibles, net140161179
Long term investments422019
Note receivable - long term9347103
Other long term assets10.006.646.64
Total assets4,4554,6191,595
LIABILITIES
Accounts payable624540
Accrued expenses916343
Notes payable/short-term debt20910011
Current portion long-term debt/capital leases292219
Other current liabilities, total425215158
Total current liabilities816445270
Total long term debt1,055653305
Total debt1,293775335
Deferred income tax------
Minority interest(10)(5.08)(2.18)
Other liabilities, total111111
Total liabilities1,8711,104584
SHAREHOLDERS EQUITY
Common stock400400300
Additional paid-in capital5,9315,8122,456
Retained earnings (accumulated deficit)(3751)(2698)(1743)
Treasury stock - common------
Unrealized gain (loss)----(0.13)
Other equity, total4.801.56(2.47)
Total equity2,5843,5161,011
Total liabilities & shareholders' equity4,4554,6191,595
Total common shares outstanding400400300
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.